EGFR and non-small cell lung carcinoma: No second-generation TKIs have been successfully developed, and to date, osimertinib is the only third-generation EGFR mutant/T790M+ TKI approved by the FDA and EMA for patients with advanced T790M NSCLC who progress on a first-line EGFR TKI.